Keryx Biopharma reports 3Q loss

BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Tuesday reported a loss of $23.5 million in its third quarter.

On a per-share basis, the Boston-based company said it had a loss of 20 cents.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

The biopharmaceutical company posted revenue of $15 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $18.8 million.

Keryx Biopharma shares have increased slightly more than 6 percent since the beginning of the year. The stock has increased 35 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX